When prescribing a drug off-label for a child, what must the primary care pediatric nurse practitioner do?

When prescribing a drug off-label for a child, what must the primary care pediatric nurse practitioner do?

• A. Document anecdotal reports of previous use by other providers.
• B. Follow up daily with the parents to determine safe administration.
• C. Discuss recommendations with the parents and document their consent.
• D. Report this use to the FDA MedWatch website for tracking purposes.

Answer: (C)

When a drug is used off-label in a child, the essential step is to engage in informed, shared decision-making with the family and to document their consent. The primary care pediatric nurse practitioner must explain what off-label use means, why this chosen option is being considered, the available evidence and uncertainties, potential risks and benefits, and possible alternatives. The family's understanding and agreement are crucial, and the consent should be clearly documented in the medical record. This approach protects the patient and supports ethical practice in pediatrics. Anecdotal reports from other providers don’t replace a documented discussion and informed consent. Daily follow-up, while often appropriate, is not a formal requirement of off-label prescribing. Reporting to the FDA MedWatch program is for adverse events or safety concerns, not a routine procedural step for obtaining consent or authorizing off-label use.

When a drug is used off-label in a child, the essential step is to engage in informed, shared decision-making with the family and to document their consent. The primary care pediatric nurse practitioner must explain what off-label use means, why this chosen option is being considered, the available evidence and uncertainties, potential risks and benefits, and possible alternatives. The family's understanding and agreement are crucial, and the consent should be clearly documented in the medical record. This approach protects the patient and supports ethical practice in pediatrics.

Anecdotal reports from other providers don’t replace a documented discussion and informed consent. Daily follow-up, while often appropriate, is not a formal requirement of off-label prescribing. Reporting to the FDA MedWatch program is for adverse events or safety concerns, not a routine procedural step for obtaining consent or authorizing off-label use.